Mirvaso (Brimonidine Tartrate)

Brimonidine tartrate is a selective alpha‑2 adrenergic receptor agonist. When applied to the skin, it activates these receptors on cutaneous blood vessels, causing smooth‑muscle contraction and vasoconstriction. The reduced blood flow to the superficial dermis diminishes the visible redness characteristic of rosacea.

The dosage of Mirvaso is determined by the prescribing clinician. Typically, a thin layer of the 0.33% gel is applied once daily to the affected facial areas. Patients should follow the specific instructions provided by their healthcare professional and the product label.

The safety of Mirvaso in pregnancy and lactation has not been established. Because the product is classified as pregnancy category unknown, it should be used only if the potential benefit justifies any possible risk to the fetus. Breastfeeding mothers should discuss potential exposure with their physician.

To request Mirvaso, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirvaso belongs to the class of topical alpha‑2 adrenergic agonists, whereas many alternative rosacea products are antibiotics (e.g., metronidazole) or azelaic acid. Unlike anti‑inflammatory agents, Mirvaso directly targets vascular redness, offering rapid but temporary reduction of erythema without antimicrobial activity.

Mirvaso should be stored at room temperature, preferably below 25 °C. Keep the gel in its original container, protect it from excessive moisture and direct sunlight, and ensure the cap is tightly closed when not in use to maintain product stability.

Mirvaso is applied topically to clean, dry skin on the face. A thin film of the 0.33% gel is spread over the affected areas once daily, usually in the morning or as directed by a healthcare professional. Hands should be washed before and after application.

Serious adverse events, although rare, include allergic contact dermatitis, systemic hypotension, severe skin reactions such as Stevens‑Johnson syndrome, and ocular irritation if the product contacts the eyes. Patients should seek immediate medical attention if they experience widespread rash, swelling, or vision changes.

Mirvaso is contraindicated in individuals with known hypersensitivity to brimonidine tartrate or any component of the gel. It should also be avoided on broken, inflamed, or infected skin, and patients with uncontrolled cardiovascular conditions should consult their physician before use.